Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology produc...
Submission marks a key regulatory milestone toward bringing SEER-calibrated, imaging-based risk ass...
Eight oral presentations and six posters demonstrate advances in mammography, DBT performance, and ...
DURHAM, N.C. and SEOUL, South Korea, Nov. 20, 2025 /PRNewswire/ -- Lunit, a leading provider of AI ...
Studies reveal how the Lunit SCOPE® suite identifies immunotherapy-responsive subtypes, standardize...
The rebranding marks the first phase of Lunit's unified global identity, connecting breast health, ...
LYNNWOOD, Wash., Oct. 16, 2025 /PRNewswire/ -- Volpara Health has qualified for the American Colleg...
AI-powered histopathology demonstrates predictive value for immunotherapy outcomes in pMMR mCRC, ad...
SEOUL, South Korea and MONTREAL, Sept. 24, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading pr...
Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize b...
Lunit highlights global leadership in cancer AI alongside world health experts with dedicated APEC ...
Framework agreement with UniHA enables access to Lunit's breast AI solutions across 1,500+ French p...
Milestone European deployment underscores growing global trust in Lunit's AI for population-wide br...
SEOUL, South Korea, July 2, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI fo...
Next-generation AI solution introduces new clinical features and broader disease detection for ches...
SEOUL, South Korea, May 26, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI fo...
Building on Volpara's breast health expertise, Lunit strengthens its U.S. presence—now delivering A...
The five-year framework agreement covers phased rollout of Lunit's AI suite—including chest X-ray, ...
A Major Leap Forward in Patient Health and the Future of Mammography PHOENIX, April 23, 2025 /PRNew...
Despite strong performance from AI, fewer recalls from AI-flagged cases point to challenges in huma...
